DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR FARXIGA
All Clinical Trials for Farxiga
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02371187 ↗ | Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? | Recruiting | AstraZeneca | Phase 2 | 2015-06-01 | Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training. |
| NCT02371187 ↗ | Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? | Recruiting | Christopher Bell | Phase 2 | 2015-06-01 | Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training. |
| NCT02372955 ↗ | Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes | Recruiting | Gulf Regional Research & Educational Services, LLC | Phase 4 | 2015-02-01 | Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers clinic SBP is unknown. The primary objective of the study is to determine the effect of dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index (AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and Intravascular volume status will be recorded. The study will involve 21 subjects for a duration of 16 weeks. |
| NCT02518945 ↗ | Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Recruiting | University at Buffalo | Phase 3 | 2015-08-01 | This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction. |
| NCT02520518 ↗ | Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss? | Recruiting | AstraZeneca | Phase 2 | 2015-08-01 | Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Farxiga
Condition Name
Clinical Trial Locations for Farxiga
Trials by Country
Clinical Trial Progress for Farxiga
Clinical Trial Phase
Clinical Trial Sponsors for Farxiga
Sponsor Name
